{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009170","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.410060+00:00","generated_at":"2026-06-01T04:14:57.361739+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo","bullets":["Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.","Cohort 2 (relapsed/refractory): 55% of evaluable patients (12/23) achieved CR/CRh/CRi with same triple combination.","Most common severe adverse events: febrile neutropenia (26%) and sepsis (5%); safety consistent with backbone therapy.","Company to continue enrollment up to 98 evaluable for Cohort 1 and 54 for Cohort 2.","Results presented at EHA Congress 2024; CEO highlights potential as additional AML treatment option."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009170","json":"https://secwatch.observer/filing/0001558370-24-009170.json","markdown":"https://secwatch.observer/filing/0001558370-24-009170.md","text":"https://secwatch.observer/filing/0001558370-24-009170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/0001558370-24-009170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/bpth-20240614x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:14:57.361739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}